Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Gilead Less M&A Happy Now but Door Still Open for ‘Compelling’ Opportunities

 April 8, 2026

BioSpace

Gilead Sciences has inked three deals this year so far totaling $14.77 billion, a marked escalation of the company’s usual M A pace.

M&A / DealsRead full story

Post navigation

Medicare Advantage Insurers Will See Higher Payments as CMS Backs Off a Key Payment Update →
← With 3 quick buyouts, Gilead leans into its latest transformation

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com